Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
28842 | 198 | 27.3 | 41% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
5 | 4 | CHEMISTRY, ORGANIC//CHEMISTRY, INORGANIC & NUCLEAR//CHEMISTRY, MULTIDISCIPLINARY | 1745167 |
490 | 3 | FERROCENE//AROMATICITY//CYCLOPHANES | 23017 |
3931 | 2 | DIAGNOST THER EUT SCI//DENT PHARMACOL//ORAL TUMOR CELLS | 783 |
28842 | 1 | L HISTIDINOL//ZILASCORBH 2//SPARSOMYCIN | 198 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | L HISTIDINOL | authKW | 1244030 | 6% | 73% | 11 |
2 | ZILASCORBH 2 | authKW | 616877 | 2% | 100% | 4 |
3 | SPARSOMYCIN | authKW | 581282 | 4% | 54% | 7 |
4 | BENZYLIDENE GLUCOSE | authKW | 462658 | 2% | 100% | 3 |
5 | DEUTERATED BENZALDEHYDE DERIVATIVE | authKW | 462658 | 2% | 100% | 3 |
6 | ANTIEICOSANOIDS | authKW | 154219 | 1% | 100% | 1 |
7 | AUTOCHTHONOUS MURINE BREAST TUMOR | authKW | 154219 | 1% | 100% | 1 |
8 | BIPHENYL PYRIMIDINE | authKW | 154219 | 1% | 100% | 1 |
9 | C1210 CELLS | authKW | 154219 | 1% | 100% | 1 |
10 | CISPLATINUM AND ANTIMETABOLITE RESISTANCE | authKW | 154219 | 1% | 100% | 1 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 1935 | 51% | 0% | 101 |
2 | Pharmacology & Pharmacy | 326 | 25% | 0% | 50 |
3 | Chemistry, Medicinal | 225 | 11% | 0% | 21 |
4 | CYTOLOGY & HISTOLOGY | 78 | 1% | 0% | 2 |
5 | Chemistry, Organic | 34 | 8% | 0% | 15 |
6 | Biochemistry & Molecular Biology | 18 | 13% | 0% | 25 |
7 | Chemistry, Multidisciplinary | 11 | 8% | 0% | 16 |
8 | Biophysics | 5 | 3% | 0% | 6 |
9 | Toxicology | 3 | 2% | 0% | 4 |
10 | Chemistry, Applied | 1 | 2% | 0% | 3 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | EXPTL THER EUT CANC | 154219 | 1% | 100% | 1 |
2 | IMPERIAL CANC BIOPHYS | 154219 | 1% | 100% | 1 |
3 | IMPERIAL CANC PATHOL | 154219 | 1% | 100% | 1 |
4 | PHARMACO TOXICOL | 38553 | 1% | 25% | 1 |
5 | CANC EXPTL THER EUT | 30842 | 1% | 20% | 1 |
6 | CHEMOTHER Y CHUO KU | 30842 | 1% | 20% | 1 |
7 | CHAIR ORGAN CHEM BIOORGAN CHEM BIOTECHNOL | 25702 | 1% | 17% | 1 |
8 | TECHNOL ORGAN PHARMACEUT CHEM | 19276 | 1% | 13% | 1 |
9 | AI MNDZHOYAN FINE ORGAN CHEM | 4817 | 1% | 3% | 1 |
10 | MICROBIOL TOXICOL | 4056 | 1% | 3% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ANTICANCER RESEARCH | 4270 | 12% | 0% | 23 |
2 | INVESTIGATIONAL NEW DRUGS | 3859 | 4% | 0% | 8 |
3 | ANTI-CANCER DRUG DESIGN | 2208 | 2% | 0% | 3 |
4 | ANTI-CANCER DRUGS | 1694 | 3% | 0% | 6 |
5 | CANCER RESEARCH | 1413 | 10% | 0% | 19 |
6 | CANCER TREATMENT REPORTS | 1114 | 2% | 0% | 4 |
7 | GANN | 823 | 1% | 0% | 2 |
8 | JOURNAL OF THE NATIONAL CANCER INSTITUTE | 781 | 3% | 0% | 5 |
9 | EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 732 | 2% | 0% | 3 |
10 | CANCER CHEMOTHERAPY AND PHARMACOLOGY | 518 | 3% | 0% | 5 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | L HISTIDINOL | 1244030 | 6% | 73% | 11 | Search L+HISTIDINOL | Search L+HISTIDINOL |
2 | ZILASCORBH 2 | 616877 | 2% | 100% | 4 | Search ZILASCORBH+2 | Search ZILASCORBH+2 |
3 | SPARSOMYCIN | 581282 | 4% | 54% | 7 | Search SPARSOMYCIN | Search SPARSOMYCIN |
4 | BENZYLIDENE GLUCOSE | 462658 | 2% | 100% | 3 | Search BENZYLIDENE+GLUCOSE | Search BENZYLIDENE+GLUCOSE |
5 | DEUTERATED BENZALDEHYDE DERIVATIVE | 462658 | 2% | 100% | 3 | Search DEUTERATED+BENZALDEHYDE+DERIVATIVE | Search DEUTERATED+BENZALDEHYDE+DERIVATIVE |
6 | ANTIEICOSANOIDS | 154219 | 1% | 100% | 1 | Search ANTIEICOSANOIDS | Search ANTIEICOSANOIDS |
7 | AUTOCHTHONOUS MURINE BREAST TUMOR | 154219 | 1% | 100% | 1 | Search AUTOCHTHONOUS+MURINE+BREAST+TUMOR | Search AUTOCHTHONOUS+MURINE+BREAST+TUMOR |
8 | BIPHENYL PYRIMIDINE | 154219 | 1% | 100% | 1 | Search BIPHENYL+PYRIMIDINE | Search BIPHENYL+PYRIMIDINE |
9 | C1210 CELLS | 154219 | 1% | 100% | 1 | Search C1210+CELLS | Search C1210+CELLS |
10 | CISPLATINUM AND ANTIMETABOLITE RESISTANCE | 154219 | 1% | 100% | 1 | Search CISPLATINUM+AND+ANTIMETABOLITE+RESISTANCE | Search CISPLATINUM+AND+ANTIMETABOLITE+RESISTANCE |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | SEMB, KA , AAMDAL, S , METTE, E , INGVAR, C , GULLAKSEN, N , OSMUNDSEN, K , (1998) ZILASCORB(H-2), A LOW-TOXICITY PROTEIN SYNTHESIS INHIBITOR THAT EXHIBITS SIGNS OF ANTICANCER ACTIVITY IN MALIGNANT MELANOMA.ANTI-CANCER DRUGS. VOL. 9. ISSUE 9. P. 797 -802 | 21 | 81% | 1 |
2 | MELVIK, JE , DORNISH, JM , LARSEN, RO , BORRETZEN, B , OFTEBRO, R , PETTERSEN, EO , (1992) INVITRO MODULATING EFFECT OF THE REVERSIBLE PROTEIN-SYNTHESIS INHIBITOR ZILASCORB(H-2) ON CIS-DIAMMINEDICHLOROPLATINUM(II)-INDUCED CYTOTOXICITY.ANTICANCER RESEARCH. VOL. 12. ISSUE 1. P. 33-38 | 23 | 66% | 7 |
3 | SEMB, KA , FODSTAD, O , KLEM, B , BIBOW, K , OSMUNDSEN, K , AAMDAL, S , (1997) ZILASCORB(H-2), A NEW REVERSIBLE PROTEIN SYNTHESIS INHIBITOR: CLINICAL STUDY OF AN ORAL PREPARATION.ANTI-CANCER DRUGS. VOL. 8. ISSUE 3. P. 296 -303 | 15 | 75% | 0 |
4 | WARRINGTON, RC , CHENG, I , FANG, WD , (1994) SUSCEPTIBILITY OF HUMAN COLON-CARCINOMA CELLS TO ANTICANCER DRUGS IS ENHANCED BY L-HISTIDINOL.ANTICANCER RESEARCH. VOL. 14. ISSUE 2A. P. 367-372 | 13 | 93% | 4 |
5 | DUNSAED, CB , DORNISH, JM , OFTEBRO, R , PETTERSEN, EO , (1995) EFFECT ON CELL SURVIVAL AND PROTEIN SYNTHESIS OF BENZYLIDENE-GLUCOSE (BG) AND THE DEUTERATED ANALOGUE P-1013 IN CULTURED CELLS.ANTICANCER RESEARCH. VOL. 15. ISSUE 5B. P. 1921-1927 | 16 | 73% | 0 |
6 | DUNSAED, CB , DORNISH, JM , PETTERSEN, EO , (1995) THE BIOAVAILABILITY AND DOSE-DEPENDENCY OF THE DEUTERATED ANTITUMOR AGENT 4,6-BENZYLIDENE-D(1)-D-GLUCOSE IN MICE AND RATS.CANCER CHEMOTHERAPY AND PHARMACOLOGY. VOL. 35. ISSUE 6. P. 464-470 | 14 | 82% | 2 |
7 | WARRINGTON, RC , FANG, WD , ZHANG, L , SHIEH, M , SAIER, MH , (1996) L-HISTIDINOL SELECTIVELY MODULATES DAUNOMYCIN TOXICITY IN NORMAL AND TUMORIGENIC KIDNEY EPITHELIAL CELLS.ANTICANCER RESEARCH. VOL. 16. ISSUE 6B. P. 3629-3633 | 11 | 92% | 3 |
8 | WARRINGTON, RC , CHENG, I , ZHANG, L , FANG, WD , (1993) L-HISTIDINOL INCREASES THE VULNERABILITY OF CULTURED HUMAN LEUKEMIA AND LYMPHOMA-CELLS TO ANTICANCER DRUGS.ANTICANCER RESEARCH. VOL. 13. ISSUE 6A. P. 2107-2112 | 11 | 100% | 3 |
9 | WARRINGTON, RC , CHENG, I , FANG, W , (1991) EFFECTS OF L-HISTIDINOL ON THE PROLIFERATION AND ANTICANCER DRUG SUSCEPTIBILITY OF CULTURED B16F10-MELANOMA CELLS.ANTICANCER RESEARCH. VOL. 11. ISSUE 5. P. 1863 -1868 | 15 | 79% | 1 |
10 | DUNSAED, CB , DORNISH, JM , AASTVEIT, TE , PETTERSEN, EO , (1993) INVIVO PHARMACOKINETICS OF THE ANTITUMOR AGENT 4,6-BENZYLIDENE-D-GLUCOSE (BG) AND A DEUTERATED ANALOG 4,6-BENZYLIDENE-D1-D-GLUCOSE (P-1013) IN MICE, RATS AND DOGS.INTERNATIONAL JOURNAL OF ONCOLOGY. VOL. 2. ISSUE 1. P. 61-66 | 11 | 92% | 1 |
Classes with closest relation at Level 1 |